Get the Stockscreener App
7.3389
0.97%
-0.0811
Shattuck Labs Inc stock is traded at $7.3389, with a volume of 267.69K.
It is down -0.97% in the last 24 hours and down -2.42% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$7.42
Open:
$7.4
24h Volume:
267.69K
Relative Volume:
0.21
Market Cap:
$736.67M
Revenue:
$1,000.00K
Net Income/Loss:
$-48.81M
P/E Ratio:
-9.4855
EPS:
-0.7737
Net Cash Flow:
$-39.95M
1W Performance:
+2.91%
1M Performance:
-2.42%
6M Performance:
+83.70%
1Y Performance:
+634.80%
1-Day Range:
$7.225
$7.46
1-Week Range:
$6.93
$7.87
52-Week Range:
$0.7939
$8.33
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
7.34 | 744.70M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
VRTX
Vertex Pharmaceuticals Inc
|
515.49 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.31 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
993.60 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.34 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.60 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-26 | Resumed | Needham | Buy |
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street Zen - marketbeat.com
T. Rowe Price Investment Management (STTK) reports 15.3% stake in Shattuck Labs - Stock Titan
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade - Yahoo Finance
A Quick Look at Today's Ratings for Shattuck Labs(STTK.US), With a Forecast Between $11 to $18 - Moomoo
Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright - marketbeat.com
Shattuck Labs Inc reports results for the quarter ended June 30Earnings Summary - TradingView
H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion - Investing.com
Needham Maintains Shattuck Labs(STTK.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Several Insiders Invested In Shattuck Labs Flagging Positive News - simplywall.st
Is Shattuck Labs Inc (STTK) Overvalued Following Q2 Earnings Mis - GuruFocus
Shattuck Labs, Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 108% Upside - TradingView
West Tower Group, LLC's Shattuck Labs Inc(STTK) Holding History - GuruFocus
Shattuck Labs, Inc. Stock 12‑Month Price Target Raised to $15.43, Implies 116% Upside - TradingView
STTK Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00 - marketbeat.com
Shattuck Labs Raises Cash Reserves to $208.3 Million, Extending Runway to 2029 - Minichart
Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Hits Expectations - marketbeat.com
Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count - Kalkine Media
Shattuck Labs Q2 Results: EPS misses estimate, losses widen 50% YoY - scanx.trade
Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases - Bitget
Form 8K Shattuck Labs Inc For: 11 August By Investing.com - Investing.com South Africa
Why is Shattuck Labs stock slipping today? By Investing.com - Investing.com Canada
STTK Looks 580.0% Overvalued on GF Value™ - GuruFocus
Shattuck Labs Reports $15.2 Million Q2 Loss and 2029 Cash Runway - Quiver Quantitative
Shattuck Labs Q2 FY26 net loss widens to $15.2 million; R&D expenses rise to $11.7 million - Bitget
Shattuck Labs Reports Positive Phase 1 Data for SL-325 and Advances DR3 Pipeline with Phase 2b Crohn’s Study Planned for 2026 - Quiver Quantitative
Shattuck Labs 2Q Loss/Shr 12c >STTK - Moomoo
Shattuck Labs Inc (STTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Certain Pre-Funded Warrants of Shattuck Labs, Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Certain Common Stock of Shattuck Labs, Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Shattuck Labs, Inc. $STTK Stock Holdings Lifted by Renaissance Technologies LLC - marketbeat.com
Shattuck Labs Inc (STTK) Stock News Today - TradingKey
Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Shattuck Labs (STTK) Projected to Release Earnings on Thursday - marketbeat.com
Shattuck Labs (STTK) Slips 4.4% to $7.58 as Biotech Volatility PersistsLarge Cap Trends - dars.gov.et
STTK Q2'26 Earnings: EPS estimate is (0.12) USD - TradingView
Shattuck Labs (STTK) Q1 2026 Earnings: Narrower Loss of $0.13 Per Share Beats Estimates as Clinical Pipeline Takes Center StageCore Business Growth - dars.gov.et
STTK Q2'26 Earnings: revenue estimate is 0 USD - TradingView
STTK|Shattuck Labs Inc|Price:7.070|Chg%:-0.120 - tradingkey.com
Shattuck Labs Inc (STTK) Institutional Confidence - TradingKey
Shattuck Labs Inc (STTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
STTK|Shattuck Labs Inc|Price:7.430|Chg%:+0.340 - TradingKey
Shattuck Labs Inc (STTK) Balance Sheet - TradingKey
Shattuck Labs Inc (STTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Shattuck Labs, Inc. Revenue Breakdown – NASDAQ:STTK - TradingView
Shattuck Labs Inc (STTK) Cash Flow - TradingKey
STTK Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentFull Year Guidance - dars.gov.et
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday - The Globe and Mail
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday - The Motley Fool
STTK Initiated Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Abhinav A. | Chief Technical Officer |
Jul 02 '26 |
Option Exercise |
3.57 |
410 |
1,464 |
86,790 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 02 '26 |
Sale |
7.01 |
410 |
2,874 |
86,380 |
| Shukla Abhinav A. | Chief Technical Officer |
Jun 30 '26 |
Option Exercise |
3.57 |
23,365 |
83,413 |
109,745 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 01 '26 |
Option Exercise |
3.57 |
100 |
357 |
86,480 |
| Shukla Abhinav A. | Chief Technical Officer |
Jun 30 '26 |
Sale |
7.08 |
23,365 |
165,424 |
86,380 |
| Shukla Abhinav A. | Chief Technical Officer |
Jul 01 '26 |
Sale |
7.07 |
100 |
707 |
86,380 |
| Pandite Arundathy N. | Chief Medical Officer |
Jun 30 '26 |
Sale |
7.01 |
30,000 |
210,300 |
136,219 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):